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SUMMARY. Comparative HPLC-UV and LC-MS/MS studies of impurity profiles of a reference sample
(Xenical®, F. Hoffmann–La Roche Ltd., Switzerland) vs. generic (Lipiblock®, EMS–Sigma Pharma, a
generic drug) were carried out with ethanol extracts of commercial samples. The generic formulation con-
tained higher levels of common impurities as well as a considerable number of impurities not found in the
reference product. The detected impurity profile of Lipiblock® revealed that it most likely is based on fer-
mentation. Since the effect of the impurities is unknown, at this point fully synthetic Xenical® appears to
offer a better safety margin than Lipiblock® which, however, compares quite well to other generic formu-
lations.
